From the 10 studies included, 5 reported [42, 44–47] that AD subjects had significantly higher serum IGF-1 levels, 2 reported [48, 49] no significant difference between the two groups, and 3 reported [50–52] lower serum levels of IGF-1. This evidence concerns the gene IGF1 and Alzheimer disease.